Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas

Restricted access

Object. The management of certain meningiomas of the skull base and those involving the dural venous sinuses remains a challenge. In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas. The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.

Methods. Hydroxyurea was administered at a dosage of approximately 20 mg/kg/day to 11 women and nine men (median age 59 years, range 31–75 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple). In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant. All patients had measurable residual disease. Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery. Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.

All patients were evaluable for response to therapy. In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8–151 weeks), and two of these showed clinical improvement. One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations. In three others with benign meningiomas, progression was confirmed on neuroimages obtained after 41, 55, and 66 weeks, respectively; the 1-year freedom from progression rate was 0.93 (standard error 0.07) in patients with benign meningiomas. In three patients with atypical meningiomas, the tumors had progressed on neuroimages obtained after 12, 19, and 45 weeks, respectively. In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks. Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.

Conclusions. Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas.

Article Information

Contributor Notes

Address reprint requests to: Warren P. Mason, M.D., Princess Margaret Hospital, Suite 18–717, 610 University Avenue, Toronto, Ontario, M5G 2M9 Canada. email: warren.mason@uhn.on.ca.
Headings
References
  • 1.

    Bernstein MVillamil ADavidson Get al: Necrosis in a meningioma following systemic chemotherapy. Case report. J Neurosurg 81:2842871994Bernstein M Villamil A Davidson G et al: Necrosis in a meningioma following systemic chemotherapy. Case report. J Neurosurg 81:284–287 1994

    • Search Google Scholar
    • Export Citation
  • 2.

    Black P: Meningiomas. Neurosurgery 32:6436571993Black P: Meningiomas. Neurosurgery 32:643–657 1993

  • 3.

    Chamberlain MC: Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84:7337361996Chamberlain MC: Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84:733–736 1996

    • Search Google Scholar
    • Export Citation
  • 4.

    Elford HL: Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33:1291351968Elford HL: Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33:129–135 1968

    • Search Google Scholar
    • Export Citation
  • 5.

    Goldsmith BJWara WMWilson CBet al: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80:1952011994Goldsmith BJ Wara WM Wilson CB et al: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80:195–201 1994

    • Search Google Scholar
    • Export Citation
  • 6.

    Goodwin JWCrowley JEyre HJet al: A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15:73771993Goodwin JW Crowley J Eyre HJ et al: A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15:73–77 1993

    • Search Google Scholar
    • Export Citation
  • 7.

    Grunberg S: Role of antiprogestational therapy for meningiomas. Hum Reprod 9 (Suppl 1):2022071994Grunberg S: Role of antiprogestational therapy for meningiomas. Hum Reprod 9 (Suppl 1):202–207 1994

    • Search Google Scholar
    • Export Citation
  • 8.

    Grunberg SMRankin CTownsend Jet al: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol 20:56a2001 (Abstract)Grunberg SM Rankin C Townsend J et al: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol 20:56a 2001 (Abstract)

    • Search Google Scholar
    • Export Citation
  • 9.

    Grunberg SMWeiss MH: Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8:61651990Grunberg SM Weiss MH: Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8:61–65 1990

    • Search Google Scholar
    • Export Citation
  • 10.

    Herken RMerker HJKrowke R: Investigation of the effect of hydroxyurea on the cell cycle and the development of necrosis in the embryonic CNS of mice. Teratology 18:1031181978Herken R Merker HJ Krowke R: Investigation of the effect of hydroxyurea on the cell cycle and the development of necrosis in the embryonic CNS of mice. Teratology 18:103–118 1978

    • Search Google Scholar
    • Export Citation
  • 11.

    Hoshino TNagashima TMurovic JAet al: Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine. Cancer 58:146614721986Hoshino T Nagashima T Murovic JA et al: Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine. Cancer 58:1466–1472 1986

    • Search Google Scholar
    • Export Citation
  • 12.

    Kaba SEDeMonte FBruner JMet al: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:2712751997Kaba SE DeMonte F Bruner JM et al: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:271–275 1997

    • Search Google Scholar
    • Export Citation
  • 13.

    Kennedy BJ: Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29:105210561972Kennedy BJ: Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29:1052–1056 1972

    • Search Google Scholar
    • Export Citation
  • 14.

    Kennedy BJYarbro JW: Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA 195:103810431966Kennedy BJ Yarbro JW: Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA 195:1038–1043 1966

    • Search Google Scholar
    • Export Citation
  • 15.

    Kim JHGelbard ASPerez AG: Action of hydroxyurea on the nucleic acid metabolism and viability of HeLa cells. Cancer Res 27:130113051967Kim JH Gelbard AS Perez AG: Action of hydroxyurea on the nucleic acid metabolism and viability of HeLa cells. Cancer Res 27:1301–1305 1967

    • Search Google Scholar
    • Export Citation
  • 16.

    Kondziolka DLevy EINiranjan Aet al: Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 91:44501999Kondziolka D Levy EI Niranjan A et al: Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 91:44–50 1999

    • Search Google Scholar
    • Export Citation
  • 17.

    Krakoff IHBrown NCReichard P: Inhibition of ribonucleotide diphosphate reductase by hydroxyurea. Cancer Res 28:155915651968Krakoff IH Brown NC Reichard P: Inhibition of ribonucleotide diphosphate reductase by hydroxyurea. Cancer Res 28:1559–1565 1968

    • Search Google Scholar
    • Export Citation
  • 18.

    Lamberts SWTanghe HLAvezaat CJet al: Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55:4864901992Lamberts SW Tanghe HL Avezaat CJ et al: Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55:486–490 1992

    • Search Google Scholar
    • Export Citation
  • 19.

    Longstreth WT JrDennis LKMcGuire VMet al: Epidemiology of intracranial meningioma. Cancer 72:6396481993Longstreth WT1 Jr Dennis LK McGuire VM et al: Epidemiology of intracranial meningioma. Cancer 72:639–648 1993

    • Search Google Scholar
    • Export Citation
  • 20.

    Macdonald DRCascino TLSchold SC Jret al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:127712801990Macdonald DR Cascino TL Schold SC Jr et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280 1990

    • Search Google Scholar
    • Export Citation
  • 21.

    Marks SMWhitwell HLLye RH: Recurrence of meningiomas after operation. Surg Neurol 25:4364401986Marks SM Whitwell HL Lye RH: Recurrence of meningiomas after operation. Surg Neurol 25:436–440 1986

    • Search Google Scholar
    • Export Citation
  • 22.

    Milosevic MFFrost PJLaperriere NJet al: Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34:8178221996Milosevic MF Frost PJ Laperriere NJ et al: Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34:817–822 1996

    • Search Google Scholar
    • Export Citation
  • 23.

    Miralbell RLinggood RMde la Monte Set al: The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 37:1571641992Miralbell R Linggood RM de la Monte S et al: The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 37:157–164 1992

    • Search Google Scholar
    • Export Citation
  • 24.

    Mirimanoff RDosoretz DELinggood RMet al: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18241985Mirimanoff R Dosoretz DE Linggood RM et al: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18–24 1985

    • Search Google Scholar
    • Export Citation
  • 25.

    National Cancer Institute: Common Toxicity Criteria. Bethesda, MD: National Cancer Institute1998National Cancer Institute : Common Toxicity Criteria. Bethesda MD: National Cancer Institute 1998

    • Search Google Scholar
    • Export Citation
  • 26.

    Newman SA: Meningiomas: a quest for the optimum therapy. J Neurosurg 80:1911941994Newman SA: Meningiomas: a quest for the optimum therapy. J Neurosurg 80:191–194 1994

    • Search Google Scholar
    • Export Citation
  • 27.

    Newton HSlivka MAStevens C: Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:1651702000Newton H Slivka MA Stevens C: Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165–170 2000

    • Search Google Scholar
    • Export Citation
  • 28.

    Palma LCelli PFranco Cet al: Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 86:7938001997Palma L Celli P Franco C et al: Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 86:793–800 1997

    • Search Google Scholar
    • Export Citation
  • 29.

    Petty AMKun LEMeyer GA: Radiation therapy for incompletely resected meningiomas. J Neurosurg 62:5025071985Petty AM Kun LE Meyer GA: Radiation therapy for incompletely resected meningiomas. J Neurosurg 62:502–507 1985

    • Search Google Scholar
    • Export Citation
  • 30.

    Rachlin JRRosenblum ML: Etiology and biology of meningiomas in Al-Mefty O (ed): Meningiomas. New York: Raven Press1991 pp 2237Rachlin JR Rosenblum ML: Etiology and biology of meningiomas in Al-Mefty O (ed): Meningiomas. New York: Raven Press 1991 pp 22–37

    • Search Google Scholar
    • Export Citation
  • 31.

    Rohringer MSutherland GRLouw DFet al: Incidence and clinicopathological features of meningioma. J Neurosurg 71:6656721989Rohringer M Sutherland GR Louw DF et al: Incidence and clinicopathological features of meningioma. J Neurosurg 71:665–672 1989

    • Search Google Scholar
    • Export Citation
  • 32.

    Schrell UMRittig MGAnders Met al: Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86:8458521997Schrell UM Rittig MG Anders M et al: Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86:845–852 1997

    • Search Google Scholar
    • Export Citation
  • 33.

    Schrell UMRittig MGAnders Met al: Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:8408441997Schrell UM Rittig MG Anders M et al: Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840–844 1997

    • Search Google Scholar
    • Export Citation
  • 34.

    Taylor BW JrMarcus RB JrFriedman WAet al: The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15:2993041988Taylor BW Jr Marcus RB Jr Friedman WA et al: The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15:299–304 1988

    • Search Google Scholar
    • Export Citation
TrendMD
Cited By
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 253 233 5
Full Text Views 207 82 0
PDF Downloads 112 30 0
EPUB Downloads 0 0 0
PubMed
Google Scholar